Premium
Robust suppression of env‐ SHIV viremia in M acaca nemestrina by 3‐drug ART is independent of timing of initiation during chronic infection
Author(s) -
Peterson Christopher W.,
Younan Patrick,
Polacino Patricia S.,
Maurice Nicholas J.,
Miller Hannah W.,
Prlic Martin,
Jerome Keith R.,
Woolfrey Ann E.,
Hu ShiuLok,
Kiem HansPeter
Publication year - 2013
Publication title -
journal of medical primatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.31
H-Index - 42
eISSN - 1600-0684
pISSN - 0047-2565
DOI - 10.1111/jmp.12060
Subject(s) - viremia , viral load , raltegravir , immunology , simian immunodeficiency virus , biology , antiretroviral therapy , drug holiday , virology , human immunodeficiency virus (hiv) , medicine
Background Nonhuman primates ( NHP s) are an important model organism for studies of HIV pathogenesis and preclinical evaluation of anti‐ HIV therapies. The successful translation of NHP ‐derived data to clinically relevant anti‐ HIV studies will require better understanding of the viral strains and NHP species used and their responses to existing antiretroviral therapies ( ART ). Methods Five pigtailed macaques ( M acaca nemestrina ) were productively infected with the SIV/HIV chimeric virus SHIV‐1157 ipd3N4 following intravenous challenge. After 8 or 27 weeks, ART ( PMPA , FTC , raltegravir) was initiated. Viral load, T‐cell counts, and production of SHIV ‐specific antibodies were monitored throughout the course of infection and ART . Results ART led to a rapid and sustained decrease in plasma viral load. Suppression of plasma viremia by ART was independent of the timing of initiation during chronic infection. Conclusions We present a new NHP model of HIV infection on antiretroviral therapy, which should prove applicable to multiple clinically relevant anti‐ HIV approaches.